Skip to main
HROW

HROW Stock Forecast & Price Target

HROW Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harrow is poised for strong future growth as they continue to develop and acquire new eye care products, with a sales guidance of $350M-$360M for 2026 and a longer-term goal of $250M in 4Q27. The recent launch of two new products and the establishment of a permanent J-Code for IOPIDINE indicate the company's strong position in the market and potential for increased revenue. With a focus on growth and established partnerships with eye care centers in the US, Harrow is well-positioned to meet their revenue goals and expand their market presence.

Bears say

Harrow is seeing strong sales growth in Triesence, which could contribute significantly to net revenue and has potential for further expansion. Additionally, the permanent J code for Iopidine on July 1 may bring in more revenue from the relief of acute intra-ocular pressure increase during various procedures. However, the larger revenue impact from Iopidine is not expected until 2027.

HROW has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harrow Health Inc (HROW) Forecast

Analysts have given HROW a Strong Buy based on their latest research and market trends.

According to 7 analysts, HROW has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harrow Health Inc (HROW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.